Payment overview · 2025
General Payments
$1,593.86
80 reported records · 20 companies
Healthcare provider profile · identity verified
Robert Michael Holtrup, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · DAYTON, OH · NPI 1669604609
Verified facts
What the public records show
CMS Open Payments records show Robert Michael Holtrup, PA-C received $1,593.86 in general payments during 2025 across 80 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $418.12 | 26.2% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $298.87 | 18.8% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $225.40 | 14.1% | 13 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $75.54 | 4.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $74.02 | 4.6% | 4 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $71.56 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.16 | 4.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.27 | 3.8% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $46.36 | 2.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.26 | 2.7% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $38.22 | 2.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.19 | 2.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.21 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.18 | 1.3% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.94 | 1.1% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $17.00 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.82 | 1.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.07 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.98 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.69 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,593.86 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $340.82 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $223.04 | 11 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $143.15 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $138.48 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $126.83 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $98.28 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.18 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.83 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $75.54 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $71.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.16 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $66.16 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.27 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.92 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.41 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $46.36 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.26 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 296 | 118 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 278 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 209 | 84 |
| Lisinopril | Lisinopril | 153 | 67 |
| Losartan Potassium | Losartan Potassium | 148 | 54 |
| Omeprazole | Omeprazole | 118 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 45 |
| Famotidine | Famotidine | 93 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 34 |
| Simvastatin | Simvastatin | 87 | 35 |
| Potassium Chloride | Potassium Chloride | 77 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 76 | 30 |
| Metformin Hcl | Metformin Hcl | 76 | 30 |
| Furosemide | Furosemide | 74 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 25 |
| Montelukast Sodium | Montelukast Sodium | 67 | 28 |
| Methocarbamol | Methocarbamol | 60 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 27 |
| Sertraline Hcl | Sertraline Hcl | 60 | 13 |
| Ibuprofen | Ibuprofen | 59 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 20 |
| Hydrocortisone | Hydrocortisone | 47 | 24 |
| Carvedilol | Carvedilol | 46 | 17 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 15 |
| Eliquis | Apixaban | 42 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 19 |
| Buspirone Hcl | Buspirone Hcl | 38 | 17 |
| Gabapentin | Gabapentin | 38 | 15 |
| Trazodone Hcl | Trazodone Hcl | 38 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 13 |
| Clonidine Hcl | Clonidine Hcl | 36 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 19 |
| Myrbetriq | Mirabegron | 35 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | 13 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | 14 |
| Glipizide | Glipizide | 27 | 12 |
| Lidocaine | Lidocaine | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | 14 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Naproxen | Naproxen | 21 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 17 |
| Allopurinol | Allopurinol | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Niacin Er | Niacin | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Atenolol | Atenolol | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,593.86 · 80 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, BREZTRI, CAPLYTA, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GVOKE HYPOPEN, JARDIANCE, Kerendia, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, RHYTHM EXPRESS, Rybelsus, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VENASEAL, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZORYVE, ZTLido | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error